{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:41:57Z","timestamp":1761460917235,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":4263,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.7861\/clinmedicine.12-4-324","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T18:27:28Z","timestamp":1361298448000},"page":"324-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Compliance with NICE guidance on the use of anti-TNF\u03b1 agents in ankylosing spondylitis: an East and West Midlands regional audit"],"prefix":"10.1016","volume":"12","author":[{"given":"Frances","family":"Rees","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Peffers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Obrenovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravinder","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Packham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Erb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2008","series-title":"Adalimumab, etanercept and infliximab for ankylosing spondylitis","key":"10.7861\/clinmedicine.12-4-324_bib1"},{"key":"10.7861\/clinmedicine.12-4-324_bib2","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","article-title":"Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study","volume":"42","author":"Clegg","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.12-4-324_bib3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.12-4-324_bib6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-324_bib7","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial (ATLAS)","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.12-4-324_bib8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"year":"2001","series-title":"Golimumab for the treatment of ankylosing spondylitis","key":"10.7861\/clinmedicine.12-4-324_bib9"},{"key":"10.7861\/clinmedicine.12-4-324_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria","volume":"27","author":"Van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.12-4-324_bib11","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"Rheumatology"},{"year":"2008","series-title":"Ankylosing spondylitis \u2013 adalimumab, etanercept and infliximab: audit support","key":"10.7861\/clinmedicine.12-4-324_bib12"},{"key":"10.7861\/clinmedicine.12-4-324_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/rheumatology\/keh669","article-title":"BSR guidelines for prescribing TNF-a blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology","volume":"44","author":"Keat","year":"2005","journal-title":"Rheumatology"},{"year":"2007","series-title":"Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis NICE technology appraisal guidance 130","key":"10.7861\/clinmedicine.12-4-324_bib14"},{"key":"10.7861\/clinmedicine.12-4-324_bib15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","article-title":"Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.7861\/clinmedicine.12-4-324_bib4","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.7861\/clinmedicine.12-4-324_bib5","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824022760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824022760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.12-4-324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:35:59Z","timestamp":1761460559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824022760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1470211824022760"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.12-4-324","relation":{},"ISSN":["1470-2118"],"issn-type":[{"type":"print","value":"1470-2118"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compliance with NICE guidance on the use of anti-TNF\u03b1 agents in ankylosing spondylitis: an East and West Midlands regional audit","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.12-4-324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2012. All rights reserved.","name":"copyright","label":"Copyright"}]}}